Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Akums Drugs and Pharmaceuticals Ltd
Free Cash Flow
Akums Drugs and Pharmaceuticals Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
|
Free Cash Flow
₹1.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Free Cash Flow
₹540m
|
CAGR 3-Years
-71%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Free Cash Flow
₹2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
O
|
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
|
Free Cash Flow
-₹2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sai Life Sciences Ltd
NSE:SAILIFE
|
Free Cash Flow
-₹552.4m
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Anthem Biosciences Ltd
NSE:ANTHEM
|
Free Cash Flow
₹1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Akums Drugs and Pharmaceuticals Ltd
Glance View
Akums Drugs and Pharmaceuticals Ltd., an unsung hero within India's healthcare sector, crafts its narrative through a robust commitment to pharmaceutical manufacturing. Founded in 2004, this company quietly emerged as a formidable provider of contract drug manufacturing solutions. Instead of marketing its own branded products, Akums positions itself as the silent partner behind many well-known pharmaceutical names, providing vital production services. By offering end-to-end manufacturing, from raw material sourcing to finished product packaging, Akums ensures that pharmaceutical companies can concentrate on their strengths: marketing and distribution. The company thrives on its vast portfolio, which encompasses the manufacture of nearly every form of a pharmaceutical product—be it tablets, capsules, injectables, or topical treatments. Akums drives revenue through partnerships, where it functions as the backbone of production lines for its clients. Utilizing cutting-edge technology and stringent global standards, Akums not only addresses the varied needs of the pharmaceutical industry but also adapts to the ever-evolving demands of healthcare worldwide. This strategic focus on high-quality contract manufacturing fuels its financial success, allowing it to expand facilities and scale operations, while maintaining a discreet presence that underscores its core philosophy: to innovate in service rather than spotlight.
See Also
What is Akums Drugs and Pharmaceuticals Ltd's Free Cash Flow?
Free Cash Flow
1.9B
INR
Based on the financial report for Mar 31, 2025, Akums Drugs and Pharmaceuticals Ltd's Free Cash Flow amounts to 1.9B INR.
What is Akums Drugs and Pharmaceuticals Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 1Y
3%
Over the last year, the Free Cash Flow growth was 3%.